Prof Woolard Isaac leads one of the few laboratories in the world capable of monitoring complex cardiovascular responses in conscious animals. Her in vivo laboratory is internationally recognised for its unique capability to measure regional blood flow across three distinct vascular beds in conscious subjects. This expertise has enabled her to secure major external research grants and foster impactful collaborations with industry partners including AstraZeneca, Promega, Heptares, and Medicines Discovery Catapult. She has also established major international research collaborations with teams across Europe, the USA, and Australia. She is a co-applicant on a £2 million MRC programme grant and serves as Principal Investigator on a recently awarded £4.5 million Wellcome Trust four-year PhD programme in Drug Discovery and Team Science. Additionally, she is the Nottingham lead on a €3.8 million European Commission-funded Marie Skłodowska-Curie Actions ITN INSPIRE project (INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late-stage drug attrition). Since January 2021, she has served as the Nottingham Director of the £10 million Centre of Membrane Proteins and Receptors (COMPARE), following her role as Deputy Director since the Centre’s inception. In 2020, she was awarded a Fellowship by the British Pharmacological Society and received the Vice-Chancellor’s Medal from the University of Nottingham in recognition of her contributions to Team Science. More recently, she was honoured with the BPS/AstraZeneca EDI Prize for her continued leadership in research culture development. Her research has led to highly cited publications in the areas of cancer and angiogenesis, with recent high-impact papers published in Cell Chemical Biology, Communications Biology, FASEB Journal, British Journal of Pharmacology, and Biochemical Pharmacology. Her work focuses on elucidating the molecular pharmacology of vascular endothelial growth factor (VEGF-A) isoforms and VEGFR2 receptors. She has contributed to the development of fluorescent ligands to study VEGFR2 (in collaboration with Promega), and has applied NanoBRET approaches to monitor GPCR target engagement in tumours in vivo (in partnership with Monash University). Her laboratory continues to explore the mechanisms underlying the hypertensive effects of receptor tyrosine kinase inhibitors, particularly those targeting VEGF pathways. In September 2024, she assumed the role of Associate Pro-Vice-Chancellor for the Research Academy and Research Culture Development. As a member of the University of Nottingham’s senior strategic leadership team, she is focused on enhancing student engagement, experience, and learning. Her aim is to ensure the University remains at the forefront of research and teaching excellence, particularly at the postgraduate level. Central to this is her commitment to supporting supervisory teams, fostering an exceptional research environment, and ensuring the student voice is valued and aligned with the University’s strategic priorities.